Gesynta Pharma

About Gesynta Pharma

Gesynta Pharma AB is a clinical-stage pharmaceutical company founded in 2017, focusing on developing treatments for chronic inflammatory diseases. The company's research and development are rooted in scientific discoveries from the Karolinska Institutet in Sweden. The founders include Patric Stenberg, Ralf Morgenstern, Gunilla Ekstrom, Charlotte Edenius, Per-Johan Jakobsson, and Urban Paulsson, who bring extensive experience from various roles within the life science and pharmaceutical industries. Stenberg serves as CEO, holding a PhD in Pharmaceutics and over 20 years of industry experience.

The company's core strategy is to inhibit microsomal prostaglandin E synthase-1 (mPGES-1), an enzyme that is a key driver of inflammation and pain. This approach aims to reduce pro-inflammatory prostaglandin E2 (PGE2) with higher precision than currently available treatments, potentially offering a safer alternative to NSAIDs. The business model centers on advancing its drug candidates through clinical trials to address significant unmet medical needs in markets with limited effective treatment options.

Gesynta Pharma's lead drug candidate is vipoglanstat (GS-248), a non-hormonal, oral inhibitor of mPGES-1. It is currently in Phase II clinical development for the treatment of endometriosis, a chronic inflammatory disease affecting approximately 10% of women of reproductive age worldwide. Preclinical studies have shown that vipoglanstat can reduce both pain and the number of endometriotic lesions, suggesting disease-modifying potential. The company's second candidate, GS-073, which shares the same mechanism of action, is entering Phase I trials for chronic inflammatory pain. Both vipoglanstat and GS-073 originated from assets acquired from AstraZeneca and Orexo AB.

Gesynta Pharma is a privately held company supported by a strong base of investors. It has successfully raised significant capital through multiple funding rounds, including a Series B round that secured SEK 304 million in January 2025 and was later extended to a total of SEK 347 million. Key investors include Industrifonden, Hadean Ventures, Linc, Innovestor Life Science, HealthCap, and several US-based specialist investors.